UBS AM’s Colgate-Palmolive CL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$582M Buy
6,828,964
+811,750
+13% +$72.3M 0.12% 152
2025
Q4
$475M Sell
6,017,214
-81,281
-1% -$6.37M 0.1% 167
2025
Q3
$488M Sell
6,098,495
-1,083,552
-15% -$92.4M 0.11% 166
2025
Q2
$653M Buy
7,182,047
+1,249,793
+21% +$114M 0.13% 144
2025
Q1
$556M Sell
5,932,254
-367,735
-6% -$32.9M 0.14% 147
2024
Q4
$573M Buy
6,299,989
+632,653
+11% +$60.4M 0.13% 137
2024
Q3
$588M Sell
5,667,336
-365,109
-6% -$37.2M 0.15% 123
2024
Q2
$585M Buy
6,032,445
+1,594,730
+36% +$147M 0.17% 107
2024
Q1
$400M Sell
4,437,715
-507,776
-10% -$43M 0.14% 140
2023
Q4
$394M Buy
4,945,491
+320,391
+7% +$24.1M 0.16% 129
2023
Q3
$329M Sell
4,625,100
-848,602
-16% -$63.4M 0.15% 141
2023
Q2
$411M Hold
5,473,702
0.2% 107
2023
Q1
$411M Buy
5,473,702
+357,898
+7% +$26.6M 0.2% 107
2022
Q4
$403M Sell
5,115,804
-170,110
-3% -$12.8M 0.21% 105
2022
Q3
$371M Sell
5,285,914
-171,997
-3% -$13.5M 0.21% 96
2022
Q2
$437M Buy
5,457,911
+2,159
+0% +$169K 0.23% 83
2022
Q1
$414M Buy
5,455,752
+318,105
+6% +$25.2M 0.18% 115
2021
Q4
$438M Buy
5,137,647
+404,612
+9% +$31.6M 0.17% 126
2021
Q3
$358M Buy
4,733,035
+149,053
+3% +$11.8M 0.15% 148
2021
Q2
$373M Buy
4,583,982
+107,177
+2% +$8.76M 0.16% 136
2021
Q1
$353M Sell
4,476,805
-68,643
-2% -$5.38M 0.16% 133
2020
Q4
$389M Buy
4,545,448
+505,307
+13% +$41.8M 0.18% 111
2020
Q3
$312M Buy
4,040,141
+80,032
+2% +$6.1M 0.17% 119
2020
Q2
$290M Sell
3,960,109
-69,687
-2% -$4.95M 0.18% 116
2020
Q1
$267M Buy
4,029,796
+346,472
+9% +$24.4M 0.19% 103
2019
Q4
$254M Buy
3,683,324
+259,758
+8% +$17.7M 0.16% 128
2019
Q3
$252M Sell
3,423,566
-49,440
-1% -$3.59M 0.17% 121
2019
Q2
$249M Sell
3,473,006
-73,357
-2% -$5.21M 0.18% 110
2019
Q1
$243M Buy
3,546,363
+236,829
+7% +$15.3M 0.18% 111
2018
Q4
$197M Buy
3,309,534
+119,635
+4% +$7.48M 0.17% 123
2018
Q3
$214M Buy
3,189,899
+24,080
+0.8% +$1.6M 0.16% 133
2018
Q2
$205M Sell
3,165,819
-388,521
-11% -$25.4M 0.16% 143
2018
Q1
$255M Buy
3,554,340
+69,888
+2% +$5.03M 0.2% 107
2017
Q4
$263M Buy
3,484,452
+1,005,125
+41% +$73.4M 0.22% 96
2017
Q3
$181M Sell
2,479,327
-29,869
-1% -$2.15M 0.16% 128
2017
Q2
$186M Sell
2,509,196
-23,521
-0.9% -$1.75M 0.18% 125
2017
Q1
$185M Buy
2,532,717
+253,665
+11% +$17.8M 0.19% 121
2016
Q4
$149M Sell
2,279,052
-526,127
-19% -$36.1M 0.17% 136
2016
Q3
$208M Sell
2,805,179
-86,569
-3% -$6.4M 0.22% 100
2016
Q2
$212M Sell
2,891,748
-59,276
-2% -$4.22M 0.24% 92
2016
Q1
$208M Sell
2,951,024
-92,492
-3% -$6.15M 0.24% 87
2015
Q4
$203M Sell
3,043,516
-673,930
-18% -$44.8M 0.23% 86
2015
Q3
$236M Sell
3,717,446
-356,168
-9% -$23.3M 0.26% 79
2015
Q2
$266M Sell
4,073,614
-144,903
-3% -$9.83M 0.26% 89
2015
Q1
$293M Sell
4,218,517
-159,081
-4% -$11M 0.28% 78
2014
Q4
$303M Sell
4,377,598
-80,189
-2% -$5.42M 0.29% 78
2014
Q3
$291M Sell
4,457,787
-16,319
-0.4% -$1.08M 0.29% 74
2014
Q2
$305M Buy
4,474,106
+20,345
+0.5% +$1.36M 0.31% 70
2014
Q1
$289M Buy
4,453,761
+168,750
+4% +$10.6M 0.31% 73
2013
Q4
$279M Buy
4,285,011
+66,397
+2% +$4.25M 0.32% 70
2013
Q3
$250M Sell
4,218,614
-662,351
-14% -$39.2M 0.31% 76
2013
Q2
$280M Buy
+4,880,965
New +$290M 0.36% 62

Other funds holding CL

UBS AM's CL Position: Q1 2026 in Review

UBS AM increased its Colgate-Palmolive (CL) stake by 13% in Q1 2026, buying an estimated $72.3M and bringing the position to 6,828,964 shares worth $582M. The position accounts for 0.12% of the portfolio, ranked #152.

UBS AM first reported a position in CL in Q2 2013 and has held it in 52 quarters since. The position peaked at $653M in Q2 2025. 1,946 funds tracked by Wall St. Rank hold CL as of Q1 2026.

  • UBS AM held 6,828,964 shares of Colgate-Palmolive worth $582M as of Q1 2026.
  • UBS AM bought 811,750 Colgate-Palmolive shares in Q1 2026, an estimated $72.3M.
  • Colgate-Palmolive made up 0.12% of UBS AM's portfolio in Q1 2026, its #152 holding.
  • UBS AM first reported a position in Colgate-Palmolive in Q2 2013 and has held it in 52 quarters since.
  • UBS AM's Colgate-Palmolive position peaked at $653M in Q2 2025.
  • 1,946 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.